• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Caribou Biosciences Inc.

    2/25/26 5:16:32 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRBU alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001754067
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CARIBOU BIOSCIENCES, INC.
    SEC File Number
    001-40631
    Address of Issuer
    2929 7TH STREET, SUITE 105
    BERKELEY
    CALIFORNIA
    94710
    Phone
    510-982-6030
    Name of Person for Whose Account the Securities are To Be Sold
    TIMOTHY KELLY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    622812050.569346803802/25/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/20/2026Restricted StockIssuerCheckbox not checked622802/20/2026Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Timothy Kelly
    2929 7TH STREET, SUITE 105
    BERKELEY � CA � 94710
    Common02/24/202631476162.14

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/25/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Timothy Patrick Kelly

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CRBU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRBU

    DatePrice TargetRatingAnalyst
    6/3/2024$13.00 → $3.00Outperform → In-line
    Evercore ISI
    11/8/2023Neutral
    Cantor Fitzgerald
    10/31/2023$13.00Outperform
    Evercore ISI
    7/11/2023$23.00Buy
    Truist
    2/18/2022$22.00Outperform
    RBC Capital
    2/14/2022$19.00Buy
    Brookline Capital
    12/1/2021$36.00Outperform
    Oppenheimer
    11/30/2021$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Kelly Timothy P was granted 45,000 shares and sold $6,168 worth of shares (3,147 units at $1.96), increasing direct ownership by 112% to 79,353 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:41 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Mcclung Barbara G was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 9% to 481,564 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:36 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Business Officer Khan Ruhi Ahmad was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 57% to 104,998 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:04 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Caribou Biosciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

    6/3/24 7:23:52 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Caribou Biosciences

    Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

    11/8/23 7:19:33 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI initiated coverage on Caribou Biosciences with a new price target

    Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

    10/31/23 8:58:42 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    3/17/25 8:01:22 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Ryali Sriram bought $24,651 worth of shares (17,360 units at $1.42) (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    1/30/25 4:02:12 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caribou Biosciences to Participate in Upcoming Investor Conferences

    BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ETWebcast For more information and link to the Leerink webcast, please visit the Events page on Caribou's website. The webcast will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Cari

    2/12/26 4:05:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

    Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L LBCL patients CB-011 CaMMouflage phase 1 translational and clinical data correlate CAR-T cell expansion with deep, durable responses and support the regimen selected for dose expansion BERKELEY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced presentations at the 2026 Tandem

    2/4/26 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

    VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physicians combat cancer's most resistant forms. Targeted therapies and immunotherapies are increasingly offering viable alternatives to chemotherapies that have stood for decades as treatment mainstays[2], replacing blunt cytotoxic approaches with precision mechanisms that attack cancer cells while preserving healthy tissue. This pivot toward precision efficacy drives the investment thesis for GT Biopharma, Inc. (NASDAQ:GTBP), Lyell Immunopharma, Inc. (NASDAQ:

    12/24/25 6:00:00 AM ET
    $CRBU
    $GTBP
    $LYEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CRBU
    SEC Filings

    View All

    SEC Form 144 filed by Caribou Biosciences Inc.

    144 - Caribou Biosciences, Inc. (0001619856) (Subject)

    2/25/26 9:41:08 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Caribou Biosciences Inc.

    144 - Caribou Biosciences, Inc. (0001619856) (Subject)

    2/25/26 5:16:32 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Caribou Biosciences Inc.

    10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)

    11/12/25 4:09:50 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Financials

    Live finance-specific insights

    View All

    Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

    First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data

    11/3/25 7:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

    Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient settingData highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCLConference c

    11/3/25 7:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

    6/2/24 7:00:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

    SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    12/6/24 4:06:56 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 7:53:54 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 6:08:51 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Leadership Updates

    Live Leadership Updates

    View All

    Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

    BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

    1/2/25 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

    -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

    8/12/24 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

    -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

    7/9/24 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care